Aysha Alneyadi,Zohra Nausheen Nizami,Hanan E. Aburawi,Soleiman Hisaindee,Muhammad Nawaz,Samir Attoub,Gaber Ramadan,Nehla Benhalilou,Mazoun Al Azzani,Yassine Elmahi,Aysha Almeqbali,Khalid Muhammad,Ali H. Eid,Ranjit Vijayan,Rabah Iratni
Synthesis of New Chromene Derivatives Targeting Triple-Negative Breast Cancer Cells
microtubules,senescence,chromenes,mitotic slippage,multinucleation,apoptosis
Simple Summary To date, breast cancer remains a leading cause of cancer-related deaths among women. The triple-negative breast cancer (TNBC) subtype is the most aggressive and invasive form, and it frequently develops resistance to chemotherapy. Hormonal therapy can also be ineffective against TNBC. Herein, we synthesized two new chromene compounds and tested their activity against hormone-responsive and TNBC cells. We found that both compounds specifically inhibited the proliferation of TNBC cells with little or no effect on hormone-responsive cells. We found that our compounds disrupted the polymerization of microtubules within the cytoskeleton, which are required for proper cell division. Consequently, the TNBC cells underwent permanent growth arrest and cell death. Moreover, the chromene compounds efficiently blocked TNBC migration and inhibited the formation of blood vessels; these are two events crucial for cancer metastasis. Our findings highlight the therapeutic potential of these compounds against TNBC. Abstract Breast cancer continues to be the leading cause of cancer-related deaths among women worldwide. The most aggressive type of breast cancer is triple-negative breast cancer (TNBC). Indeed, not only does TNBC not respond well to several chemotherapeutic agents, but it also frequently develops resistance to various anti-cancer drugs, including taxane mitotic inhibitors. This necessitates the search for newer, more efficacious drugs. In this study, we synthesized two novel chromene derivatives (C1 and C2) and tested their efficacy against a battery of luminal type A and TNBC cell lines. Our results show that C1 and C2 significantly and specifically inhibited TNBC cell viability but had no effect on the luminal A cell type. In addition, these novel compounds induced mitotic arrest, cell multinucleation leading to senescence, and apoptotic cell death through the activation of the extrinsic pathway. We also showed that the underlying mechanisms for these actions of C1 and C2 involved inhibition of microtubule polymerization and disruption of the F-actin cytoskeleton. Furthermore, both compounds significantly attenuated migration of TNBC cells and inhibited angiogenesis in vitro. Finally, we performed an in silico analysis, which revealed that these novel variants bind to the colchicine binding site in β-tubulin. Taken together, our data highlight the potential chemotherapeutic properties of two novel chromene compounds against TNBC.
Synthesis of New Chromene Derivatives Targeting Triple-Negative Breast Cancer Cells

To date, breast cancer remains a leading cause of cancer-related deaths among women. The triple-negative breast cancer (TNBC) subtype is the most aggressive and invasive form, and it frequently develops resistance to chemotherapy. Hormonal therapy can also be ineffective against TNBC. Herein, we synthesized two new chromene compounds and tested their activity against hormone-responsive and TNBC cells. We found that both compounds specifically inhibited the proliferation of TNBC cells with little or no effect on hormone-responsive cells. We found that our compounds disrupted the polymerization of microtubules within the cytoskeleton, which are required for proper cell division. Consequently, the TNBC cells underwent permanent growth arrest and cell death. Moreover, the chromene compounds efficiently blocked TNBC migration and inhibited the formation of blood vessels; these are two events crucial for cancer metastasis. Our findings highlight the therapeutic potential of these compounds against TNBC.

Breast cancer continues to be the leading cause of cancer-related deaths among women worldwide. The most aggressive type of breast cancer is triple-negative breast cancer (TNBC). Indeed, not only does TNBC not respond well to several chemotherapeutic agents, but it also frequently develops resistance to various anti-cancer drugs, including taxane mitotic inhibitors. This necessitates the search for newer, more efficacious drugs. In this study, we synthesized two novel chromene derivatives (C1 and C2) and tested their efficacy against a battery of luminal type A and TNBC cell lines. Our results show that C1 and C2 significantly and specifically inhibited TNBC cell viability but had no effect on the luminal A cell type. In addition, these novel compounds induced mitotic arrest, cell multinucleation leading to senescence, and apoptotic cell death through the activation of the extrinsic pathway. We also showed that the underlying mechanisms for these actions of C1 and C2 involved inhibition of microtubule polymerization and disruption of the F-actin cytoskeleton. Furthermore, both compounds significantly attenuated migration of TNBC cells and inhibited angiogenesis in vitro. Finally, we performed an in silico analysis, which revealed that these novel variants bind to the colchicine binding site in β-tubulin. Taken together, our data highlight the potential chemotherapeutic properties of two novel chromene compounds against TNBC.

Breast cancer remains the world’s most prevalent cancer type and is one of the leading causes of cancer-related mortality [1]. In 2020, approximately 2.3 million women were diagnosed with breast cancer and of these, 684,996 died, representing approximately 16% of all cancer deaths in women worldwide [1,2]. Moreover, the occurrence rate of breast cancer is constantly increasing, with over three million new cases and one million associated deaths predicted by 2040 [1]. Breast cancer is a highly heterogeneous disease both clinically and genetically. It can be classified into four subtypes based on the immunohistochemical expression of the following hormone receptors: human epidermal growth factor receptor (HER2), progesterone receptor (PR), and estrogen receptor (ER) [3] as luminal A, luminal HER2-positive, and triple-negative breast cancer (TNBC) [3]. Compared to other subtypes, TNBC, which lacks expression of all three receptors, is characterized by a high proliferative index, high invasiveness, poor prognosis, early relapse, and a tendency to be diagnosed in advanced stages [3,4,5]. The three aforementioned hormone receptors are frequently targeted biomarkers in breast cancer treatment, and absence of their expression makes conventional chemotherapeutic and hormonal therapies relatively ineffective against TNBC. This makes TNBC the most aggressive and lethal subtype of breast cancer [6]. TNBC can evade apoptosis through its resistance to several cytotoxic drugs used to treat it, including cyclophosphamide, doxorubicin, and paclitaxel [7,8]. In addition, many agents used to treat cancers, including TNBC, have been shown to have major drawbacks in terms of drug resistance, adverse effects, and toxicity [9]. Thus, there is a need to discover and develop novel anticancer agents that can specifically target TNBC. Chromenes refer to a class of bicyclic oxygen-containing heterocycles with a fused benzene ring. They are natural compounds that are widely distributed in various plant species, with four common and readily identifiable structural motifs, namely 2H-chromene, 4H-chromene, 2H-chromene-2-one, and 4H-chromen-4-one [10] (Figure 1). The 4H-chromenes, in particular, are emerging as potent novel anticancer agents [11,12]. Their anticancer activity has been observed in many natural compounds, such as tephrosin against lung and pancreatic cancer [13,14], calanone against cervical carcinoma [15], acronycine against ovarian, lung, and colon cancer [16], and seselin against skin cancer [17]. The structure of the chromenes offers advantages that make them appealing candidates for the development of new anticancer drugs. They are easily accessible through a single-step three component condensation reaction comprising of a phenol, a methylene-active derivative, and aryl aldehydes. Moreover, the products are crystalline and easily purified following bulk synthesis. In addition, the chromene scaffold offers unique opportunities for the introduction of functional groups that can influence their biological activity against cancer. Several modified 4H-chromenes were shown to be effective, albeit at nanomolar concentrations, against various human cancers [18,19,20,21,22]. In some cases, they were found to be effective even against chemo-resistant cancer such as multi-drug resistant HL60/MX22 [22] and cisplatin resistant ovarian cancer such as OVCAR-3, A2780-cisR, and TOV112D [23]. The molecular mechanism of the action of these 4H-chromenes against various types of human cancers does not seem to be restricted to one mechanism, and involves several pathways that include apoptosis, cell cycle arrest, nuclear fragmentation, microtubule depolarization, and tumor vasculature disruption [24,25]. The 4-Aryl-4H-chromene-3-carbonitrile derivatives, for example, were reported to effectively inhibit Src kinases, which are overexpressed in human colorectal and leukemia cell lines [26]. Crolibulin, another 4H-chromene derivative, (currently in Phase I/II clinical trials for the treatment of advanced solid tumors) induces depolarization of the microtubules and disruption of tumor vasculature [24]. These findings suggest that 4H-chromene compounds are promising candidates for cancer therapy as they are easily accessible, and they operate against a wide range of targets, thus having the ability to prevent the development of drug-resistant cancers such as TNBC. In this paper, we synthesized two new variants of 4H-chromene compounds, C1 and C2, and tested their anticancer activity against four cell lines, including two luminal A and two TNBC cancer cell lines.

Human breast cancer cells MDA-MB-231(300275), MCF-7 (300273), and T47D (300353) were obtained from Cell Line Service, Eppelheim, Germany, and Hs578T was obtained from ATCC. MDA-MB-231, Hs578T, and MCF-7 were maintained in DMEM (11995073; Gibco/Thermo Fisher Scientific, Waltham, MA, USA), whereas T47D was maintained in RPMI (1770766; Gibco, Waltham, MA, USA). Culture media were supplemented with fetal bovine serum (10%) (A4766801; Gibco) and 100 U/mL penicillin/streptomycin/glutamine (2321073; Gibco). Human umbilical vein endothelial cells (HUVECs; Millipore, Burlington, MA, USA) were cultured in an EndoGROTM basal medium supplemented with an EndoGRO-VEGF supplement kit (SCME-002S, Merck Millipore, Burlington, MA, USA). Antibodies against p27 (3686), caspase 8 (9746), anti-mouse IgG-HRP (7076P2), and anti-rabbit IgG-HRP (7074S) were obtained from Cell Signaling (Danvers, MA, USA). Antibodies against α-tubulin (SC-53646), β-tubulin (SC-5274), and β-actin (sc47778) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Antibodies against H3pSer10 (51336), γH2AX (07-164), and p21 (05-655) were obtained from Millipore. Finally, an antibody against cleaved PARP was obtained from Abcam (Ab9739) (Cambridge, UK) and an antibody against p16 (554079) was obtained from BD Pharmingen (Franklin Lakes, NJ, USA).

Five thousand cells from MDA-MB-231, Hs578T, T47D, and MCF-7 were seeded in triplicate in 96-well cell culture plates. After 24 h of culture, cells were treated with various concentrations of chromenes C1 and C2 or a control. Cell viability was assessed 24 and 48 h post-treatment using an MTT assay kit (ab 211091; Abcam) with all procedures performed as per the manufacturer’s specifications. The cellular viability was further assessed by using a method that distinguished between viable and dead cells based on their selective permeability to two DNA binding dyes. Cell viability was carried out as previously described [27] using the Muse® Count & Viability Kit. Briefly, on the day of treatment, considered as day 0, cells were counted to determine the number of cells per well before adding chromene C1 and C2. Viable cells were determined using the Muse™ Cell Analyzer as described by the manufacturer (Luminex Corporation, Austin, TX, USA).

TNBC cells (250 per well) were cultured in a 6-well cell culture plate for 3 days before adding freshly prepared growth medium with or without various concentrations of chromene C1 or C2. Cells were then grown for 8–9 days to allow for the formation of colonies. Colonies were then washed with PBS, fixed with formalin solution (10%), and stained with crystal violet.

Cell cycle distributions of untreated and chromene C1- and C2-treated MDA-MB-231 and Hs578T cells were analyzed using a Muse™ Cell Cycle Kit (Millipore), with all procedures following the instructions provided by the manufacturer. Cells grown in 6 cm dishes were treated with or without C1 and C2 for 24 h. Cell cycle analysis was then performed as previously described [27], using the Muse™ Cell Analyzer. All data collected were analyzed using FlowJo version 7.6.5.

Samples of 5000 MB-231 cells seeded into 96-well cell culture plates were treated with or without chromene C1 or C2 for 24 h. Caspase 3 and 7 activity was then measured using a luminescent assay kit (Promega Corporation, Madison, WI, USA), with all procedures performed as per the manufacturer’s instructions.

MDA-MB-231 cells (4 × 104) were cultured in a two-well chamber slide for 24 h, then exposed to chromene C1 or C2 for 24 h. Next, the cells were fixed with formalin (10), permeabilized with Triton X-100 (0.1%), preincubated with 5% non-fat dry milk, and finally incubated with α-tubulin overnight at 4 °C. After washing with PBS, the cells were incubated with a rhodamine-conjugated secondary antibody, washed again with PBS, and their DNA was stained with 4′, 6-diamine-2-phenylindole dihydrochloride (DAPI). Actin filaments in control and treated cells were visualized as follows: after fixation and permeabilization as described above, the cells were stained with rhodamine-conjugated phalloidin followed by DAPI staining. Fluorescence was visualized using a fluorescent microscope CKX53 (Olympus, Tokyo, Japan).

MDA-MB-231 and Hs 578T cells (4 × 104) were cultured on a 2-well chamber slide for 24 h, then exposed to chromene C1 or C2 for 24 h. Cells were washed twice with PBS and fixed with 3.7% glutaraldehyde for 20 min at room temperature. After fixation, cells were washed again three times with PBS and permeabilized with Triton X-100 (0.2%). Cells were washed again 3 times with PBS and then with distilled water. Cells were then stained with hematoxylin for 15 min and washed with distilled water for 2 min to remove excess stain before staining with eosin solution for 5 min. Stained cells were observed under a light microscope.

MDA-MB-231 and Hs578T cells (2.8 × 106) were seeded in 100 mm culture dishes and cultured for 24 h prior to treatment with chromene C1 or C2 at the indicated concentrations and for the listed incubation times. Following treatment, protein extraction, protein concentration quantification, and protein detection by Western blotting were conducted as previously described [27]. Protein expression was analyzed by detection of chemiluminescence using a Li-COR C-DiGit blot scanner. Densitometry quantification of the Western blots was carried out using ImageJ software. Original blots can be found at Supplementary File S2.

TNBC cells were seeded (2.5 × 105 cells/dish) in 60 mm culture dishes for 24 h and treated with DMSO (control) or chromene C1 or C2 for 48 h. Cells were then washed with PBS and fixed with 2% formaldehyde/0.2% glutaraldehyde. The activity of β-galactosidase was then quantified using a previously described method [28].

The effect of C1 and C2 on the migration of TNBC cells was assessed using a wound-healing assay. Briefly, cells were cultured in 6-well plates until confluency. Wounds were then made using a 10-μL pipette tip. After extensive washing with PBS, DMSO (control) or chromene compounds were added to the cells. The width of each wound was measured at the indicated time using an Evos XL inverted microscope at 40×. Wound closure, represented by the distance migrated (D) by cells for each wound was calculated as follows: D = width of the wound at t = 0 h − width of the wound at t = 4 or 10).

A 96-well plate was first coated with Matrigel matrix (Corning; 40–50 µL) then incubated for 1 h at 37 °C. Next, HUVECs (25,000 cells/well) were added to the coated plate along with DMSO (control) or C1 or C2 in duplicate. After 8 h, the tubes were photographed. The effect of C1 or C2 on the capacity of HUVECs to form capillary-like structures was assessed by measuring the length of newly formed tubules using Tube Formation Assay Image Analysis Solution software (WimTube, Wimasis (2016), Release 4.0, Onimagin Technologies SCA, Córdoba, Spain). To assess the impact of C1 or C2 on HUVEC viability, ~9000 cells were seeded into 96-well plates and cultured for 24 h. The cells were then treated with C1 or C2 (or a negative control). Cell viability was measured at indicated time points using a Luminescent Cell Viability kit (Promega, Madison, WI, USA), as per the manufacturer’s protocol.

MDA-MB-231 (2.8 × 106) cells were cultured in 100 mm culture dishes for 24 h before adding DMSO (control) or chromene compounds. The mixture was then left to culture for another 24 h. Control and treated cells were washed twice with pre-warmed PBS then lysed in hypotonic buffer (20 mM Tris HCl, pH 6.8, 1 mM MgCl 2, 5 mM amino caproic acid, 2 mM EGTA, 0.5% NP-40, 1 mM benzamidine, 2 mM PMSF, and 200 Units/mL aprotinin) at 37 °C for 5 min. The soluble (present in the supernatant) and polymerized tubulin (present in the pellet) fractions were separated by centrifugation at 15,000× g for 10 min at RT. The pellets were then suspended in lysis buffer and sonicated. The two fractions were then resolved by Western blotting analysis.

Three-dimensional (3D) protein structures of tubulin in complex with known inhibitors targeting distinct sites were obtained from the Protein Data Bank (PDB; https://www.rcsb.org). This included colchicine (PDB ID: 5NM5), vinblastine (PDB ID: 5J2T), laulimalide (PDB ID: 4O4H), and taxol (PDB ID: 6WVR). For each inhibitor, the inhibitor binding site harboring subunit was extracted, and its protein structure was pre-processed using Schrödinger Suite 2022-1 Protein Preparation Wizard (Schrödinger LLC, New York, NY, USA) using the default options. Hydrogen atoms were added, and the pH was set to 7 for the defining protonation states. Finally, the structures were optimized, and the energy was minimized to obtain a geometrically stable state. To facilitate molecular docking, a receptor grid was generated for each protein structure centered around the cocrystallized tubulin. In addition, the two-dimensional (2D) structure of chromenes C1 and C2 were drawn using Schrödinger Maestro and 2D Sketcher (Schrödinger LLC, New York, NY, USA). Ligand structures were then prepared for docking using Schrödinger Ligprep (Schrödinger LLC, New York, NY, USA). This step converts the 2D structure to a 3D structure, adds hydrogen atoms, generates various tautomers and ionization states, and optimizes the geometry of the molecules. Next, these structures were docked in the receptor grid of each of the proteins using Schrödinger Glide in extra precision (XP) mode [29]. The docked pose was then scored using the GlideScore scoring method [30]. We then analyzed the docked pose and visualized protein–ligand interactions using Schrödinger Maestro.

Statistical analyses were conducted using SPSS version 21. Data were presented as mean ± SEM and were analyzed using one-way ANOVA. Statistical significance was defined as follows: * p < 0.05, ** p < 0.005, and *** p < 0.001.

C1 (Supplementary Figure S1) was synthesized using a three-component reaction comprising 1-naphthol, benzaldehyde, and malonitrile in ethanol in the presence of piperidine as a catalyst. Specific details of this reaction are included in the Supplementary Materials and Methods File S1. For the initial experiments, the mixture was refluxed in an oil bath at 80 °C for 6 h. However, we found that the reaction time could be significantly reduced to 5 min using microwave irradiation (dynamic power 25–30 W) and produced comparable yields (>90%). C1 was purified by repeated recrystallization in hot ethanol. The observed structure showed good agreement between 1H NMR, 13C NMR, HRMS, and FT-IR datasets (Supplementary Figure S1a–d).

The Schiff base C2 (Supplementary Figure S2) was prepared by heating a mixture of amine C1 and salicylaldehyde in dry ethanol overnight. This procedure is described in detail in the Supplementary Materials and Methods. C2 was produced when the resulting solution was allowed to cool at room temperature, filtered, and thoroughly washed with cold ethanol. 1H NMR (Supplementary Figure S2a), 13C NMR (Supplementary Figure S2b–d), and FT-IR (Supplementary Figure S2g) data indicated the absence of aldehyde groups in C2, and mass spectra indicated a mass peak at 402.1 Daltons (Supplementary Figure S2e,f) that corresponds to C2. Moreover, 1H NMR data indicated the presence of an imine = CH peak as a singlet at δ 9.49 ppm. The methine proton at C-4 (indicated by arrow in the structure of C2) appeared as two singlets (4.85 and 5.26 ppm), suggesting the presence of diastereoisomers in almost equal proportions. Moreover, 13C NMR spectra confirmed the presence of diastereoisomers. We did not attempt to separate them as C2 readily decomposed in silica and alumina gels.

We examined the effect of the newly synthesized chromenes C1 and C2 on the viability of two ER+, PR+, and HER2− luminal A breast cancer cell lines, MCF-7 and T47D. We also tested these chromenes with two TNBC cell lines: MDA-MB-231 and Hs578T. All cell lines were treated with C1, C2, or a negative control and examined using an MTT assay after treatment for 24 and 48 h. Interestingly, we found that the two TNBC lines MDA-MB-231 and Hs578T were more sensitive to C1 (Figure 2A) and C2 (Figure 2B) than MCF-7 (Figure 2A,B), which showed moderate sensitivity, or T47D (Figure 2A,B), which showed total resistance even at the highest concentration and after long exposure to both compounds. These data indicate that our newly modified chromenes selectively target TNBC cell lines. The MTT assay measures metabolic activity and hence cannot distinguish between reduced metabolism due to cell stress or death. Therefore, we decided to further monitor the viability of C1- and C2-treated MDA-MB-231 and Hs578T cells using an assay that differentially stains dead and viable cells. As shown in Figure 3A,B, the number of untreated MDA-MBA-231 cells at day 1 increased relative to day 0, i.e., the day of treatment, whereas the number of C1- and C2-treated cells decreased compared with day 0. A similar result was also obtained for Hs578T cells (Supplementary Figure S3A,B). Taken together, our results indicate that C1 and C2 promote the death of TNBC cells. To further confirm the potential of C1 and C2 against TNBC, we attempted to determine whether these two compounds affect the colony-forming ability of MDA-MB-231 and Hs578T cells. We found that even the lowest concentrations of C1 and C2 were able to markedly inhibit the colony growth of MDA-MB-231 (Figure 3C,D) and Hs578T cells (Supplementary Figure S3C,D).

Next, we investigated whether the C1- and C2-mediated inhibition of cell viability of TNBC was mediated by activation of apoptosis by scoring markers of apoptosis. As shown in Figure 4 (for MDA-MB-231) and Supplementary Figure S4 (for Hs578T), treatment with chromenes C1 and C2 led to the accumulation of cleaved PARP and caspase 8 (an initiator caspase that is active in the extrinsic pathway) (Figure 4A,B), as well as the activation of caspase 3/7 (effector caspases) (Figure 4C). These data strongly suggest that C1 and C2 inhibit cell viability in TNBC cells, at least partially, by promoting cell death through the activation of the extrinsic apoptotic pathway.

Light microscopy observation of C1- and C2-treated MDA-MB-231 (Figure 5A) and Hs578T cells (Supplementary Figure S5A) revealed that the two chromenes induced several morphological changes. Some of the treated cells appeared small and rounded, which is characteristic of dying cells (Figure 4A, dashed arrows). Moreover, it is consistent with cell viability data. A more striking finding was the presence of a subpopulation of cells exhibiting a flattened and enlarged shape and, strikingly, a high level of multinucleation (Figure 5, plain arrow) compared with control cells (Figure 5A and Supplementary Figure S5A). The latter two are often associated with senescent cells. Multinucleation was further confirmed by examining chromene-treated MDA-MB-231 (Figure 5B) and Hs578T cells (Supplementary Figure S5B) using hematoxylin and eosin staining. We found several (2–6) nuclei of different sizes within the same cell. The frequency of chromene-induced multinucleation was 40–60% for C1 and 40–70% for C2 in MDA-MB-231 (Figure 5C,D), and 40–55% for both C1 and C2 in Hs578T (Supplementary Figure S5C,D). It has also been reported that the accumulation of double-strand DNA breaks often occurs in cells undergoing prolonged mitotic delays. Similarly, multinucleated cells were also reported to display DNA damage [31]. We then sought to investigate whether C1- and C2-mediated effects were associated with DNA damage in MDA-MB-231 and Hs578T cells. The degree of DNA damage was assessed by measuring phosphorylated H2AX (γH2AX) levels in control and chromene-treated cells. Western blotting analysis revealed considerable γH2AX accumulation, a clear indication of DNA damage, in MDA-MB-231 (Figure 5E) and Hs578T (Supplementary Figure S5E).

Cell multinucleation has been hypothesized to originate from failed mitosis [32]. This prompted us to examine the effect of C1 and C2 treatments on the progression of the cell cycle. To this effect, MDA-MB-231 and Hs578T cells were treated with and without the indicated concentrations of C1 or C2 for 24 h and were then subjected to cell cycle analysis. Treated cells exhibited a robust increase in the population of G2/M-arrested cells in both cell lines (Figure 6A–C and Supplementary Figure S5A–C). The number of G2/M-arrested cells increased for both compounds. These two cells represent up to 80% of the total cell population, a clear indication of massive cell cycle arrest. To determine if the cell cycle was specifically arrested at mitosis, we examined the phosphorylation of the marker of mitosis, namely histone H3 (H3pSer10) in cells treated with C1 or C2. An increase in the level of H3pSer10, mediated by aurora kinase, implies mitosis. As shown in Figure 6D and Supplementary Figure S6D, both chromene compounds caused a significant increase in H3pSer021 levels in both cell lines. Taken together, these data confirm that chromenes C1 and C2 induce mitotic arrest in TNBC cells. Next, we examined whether M-arrested chromene-treated cells also underwent senescence by looking at the expression of senescence-associated β-galactosidase (SA-β-Gal), a marker of senescence. We found that a significant number of cells treated with either C1 or C2 expressed SA-β-Gal (shown in blue) in MDA-MB-231 (Figure 7A–D) and Hs578T (Supplementary Figure S7A–D), respectively. Furthermore, we found that senescence occurred more frequently in multinucleated cells (Figure 7A,B, plain arrows). Taken together, our data demonstrate that chromenes C1 and C2 induce mitotic cell death and senescence in TNBC cells. The involvement of p21 and p16, two cyclin-dependent kinase inhibitors (CKIs), in the induction and/or maintenance of senescence in response to anticancer therapy is well documented. This prompted us to ask whether senescence following administration of C1 and C2 is associated with the induction of p21 and/or p16. The results of typical Western blotting analyses, presented in Figure 7E,F, demonstrate a marked increase of both p16 and p21 proteins in C1- and C2-treated MDA-MB-231 cells. This result highlights the potential involvement of these two CKIs in C1- and C2-induced cell cycle arrest and senescence.

Next, we sought to elucidate the mechanism through which C1 and C2 induce multinucleation in TNBC. Several microtubule-disrupting drugs are known to induce mitotic catastrophe associated with the accumulation of multinucleation in cancer cells. This prompted us to examine the integrity of the microtubule network in control and chromene-treated cells. MDA-MB-231 cells were treated with 1 μM of C1, C2, or a negative control for 24 h, after which they were fixed, stained with anti-α-tubulin antibody, and observed under a fluorescence microscope. In control cells, the microtubules concentrated in the perinuclear region and their extension toward the cytoplasm can be clearly seen (Figure 8A, upper panel). In contrast, no polymerized microtubule filaments were visible in C1- or C2-treated cells (Figure 8A, middle and lower panels). Instead, fluorescent α-tubulin dispersed throughout the cytoplasm, indicating a possible inhibition or defective polymerization of microtubules (Figure 8A, middle and lower panels). To test whether our chromene compounds inhibited microtubule polymerization, we examined the relative amounts of different polymers. To this end, polymers and soluble forms were separated from control and C1 or C2-treated MDA-MB-231 cells, and the amount of α-tubulin was resolved by Western blotting. As shown in Figure 8B,C, a large amount of αtubulin was present in a polymerized form in control and untreated cells. However, in cells treated with C1 (Figure 8B) or C2 (Figure 8C) at concentrations of 0.5 and 1 μM, the polymers were almost completely absent. Most of the tubulins were present in the soluble form. This result, along with immunofluorescence data, suggests that C1 and C2 act as microtubule-depolymerizing compounds. We then conducted an in silico molecular docking study to test the potential affinity of C1 and C2 for α- and β-tubulin. Chromenes C1 and C2 were docked to four distinct inhibitor binding sites in α- and β-tubulin [33]—i.e., the colchicine, laulimalide, vinblastine, and taxol binding sites of tubulin. GlideScores analysis of the docked chromenes indicated very poor scores for the laulimalide, vinblastine, and taxol binding sites. C1 and C2 seemingly docked in the colchicine binding site, which is located in the interface between β-tubulin and α-tubulin. For this site, C2 showed an XP GlideScore of −8.918 kcal/mol, whereas C1 docked with an XP GlideScore of −8.299 kcal/mol. The core of both C1 and C2 adopted a similar pose in the colchicine binding site, which overlapped with how colchicine binds in this site (Figure 8D–F). Both C1 and C2 interacted with binding site residues primarily via hydrophobic interactions, as is evident in Supplementary Figure S8. The residues that contributed most to protein–ligand interactions were Lys352, Ala316, Asn258, Leu255, Lys254, Ala250, Leu248, and Cys241 of β-tubulin and to a lesser extent Val181, Ala180, and Asn101 of α-tubulin. The hydroxyl group of C2 formed a hydrogen bond with Asn249 of β-tubulin, and the amino group of C1 formed a hydrogen bond with Asn101 of α-tubulin.

Next, we proceeded to investigate the integrity of the actin cytoskeleton. To do this, we performed fluorescence microscopy to visualize the F-actin cytoskeleton in control and C1- and C2-treated MDA-MB-231 cells via phalloidin staining. As can be seen in Figure 9, DMSO-treated MDA-MB-231 cells exhibited the expected mesenchymal-like appearance with global stress fibers (arrowheads) and regional and occasional lamellipodia (thin dashed arrows). However, after treatment with C1 or C2, patterns of complete abrogation of stress fibers were noted, and a dramatic formation of cortical actin fibers was observed (bold arrows). Moreover, treated cells were significantly larger in size than control cells. Such a major disruption in the localization of actin fibers as well as their assembly and disassembly, and the consequent aberrant cytokinesis, may explain why treated cells showed multinucleation. In addition, treated cells exhibited a more rounded morphology with no directional stress fibers, which is suggestive of migration suppression.

Cell migration and invasion are prerequisites for metastasis of TNBC from the primary tumor to distant organs. Moreover, it is well documented that the formation of fibrous strands of actin, known as F-actin, can promote cell division and migration, in addition to its role in the structural integrity of normal and cancer cells [34,35]. This prompted us to test the effect of the two chromene compounds on the migratory capacity of MDA-MB-231 and Hs578T. Our results showed that both C1 and C2 significantly inhibited the migration of highly migratory MDA-MB-231 cells (Figure 10A–D). To rule out the possibility that migration was inhibited due to the low number of cells, as a consequence of cell death, control and chromene-treated cells were collected from each well at the end of the experiment and the number of viable cells was counted. As is shown in Figure 10E,F, the number of viable cells did not decrease in chromene-treated wells compared to untreated wells.

Angiogenesis critically governs tumor growth and metastasis. Inhibiting this process can therefore inhibit tumor growth and spread. An intact cytoskeleton is critical for the various steps of angiogenesis and for the maintenance of newly formed structures [36]. We used HUVECs plated on matrigel-coated plates to examine the effect of C1 and C2 on the formation of capillary tubes in vitro. As shown in Figure 11A,B, treatment of HUVECs with either C1 or C2 compounds resulted in a significant reduction in tube formation in comparison to DMSO-treated cells after 8 h of treatment. The anti-angiogenic effect of C1 or C2 was observed in a concentration-dependent manner, with a 30% reduction observed at a concentration of 0.5 μM and a 60% reduction at a concentration of 1 μM. It is noteworthy that treatment with C1 or C2 caused only a small reduction in HUVECs’ viability after 8 h (~10%), and this effect did not further increase after 24 h of incubation with the chromene compounds (Figure 11C,D). Our results demonstrate the potent anti-angiogenic activity of the novel chromene compounds and suggest that the inhibition of tube formation occurs through disruption of mictotubules’ dynamics, and that reduction in cellular viability could account only for a very limited effect.

TNBC constitutes a large proportion of breast cancer cases in young patients [37]. This subtype of breast cancer is one of the most aggressive forms, and is both characterized by a high mitotic index and often metastatic [38]. Moreover, almost all women with metastatic TNBC die from their disease. To date, and to the best of our knowledge, there is no targeted therapy yet approved for the treatment of TNBC, most probably because the heterogeneity of this disease makes it difficult to develop specific therapeutic treatments. At present, the standard therapeutic approach relies on cytotoxic chemotherapy. In this study, we synthesized two novel chromenes, C1 and C2, that specifically target TNBC subtypes without a significant effect on hormone-responsive subtypes. Our chromenes induced mitotic arrest, cell multinucleation, and senescence. In addition, C1 and C2 both induced cell death via activation of the extrinsic apoptotic pathway. We demonstrated that C1 and C2 exert their anti-TNBC effects by binding to the colchicine binding site of β-tubulin, which leads to the destabilization of the microtubule network. Furthermore, we showed that C1 and C2 disrupt the organization of the actin filament network and inhibit cell migration. Finally, chromenes C1 and C2 display a potent antiangiogenic effect on HUVECs in vitro. Thus, our results indicate that these synthetic chromenes are potential potent new antitumor agents capable of specifically targeting TNBC subtypes. Many chromenes (both natural and synthetic) have been reported to exert an antiproliferative activity against various cancer types. However, few have been reported as being microtubule-destabilizing agents [10]. Sp-6-27, a chromene derivative, was identified as a tubulin depolymerizing agent that exerted antiproliferative activity against cisplatin-sensitive (A2780) and -resistant (cis-A2780) ovarian cancer cell lines [21]. Sp-6-27 was shown to induce G2/M arrest and apoptotic cell death by activating the intrinsic pathway and, in addition, was able to inhibit the migration of A2780 cells. Crolibulin, a 4H-chromene currently in phase I/II of clinical trials with the National Cancer Institute, has been shown to be efficacious in treating a subset of patients with anaplastic thyroid cancer [39]. Crolibulin is described as an inhibitor of tubulin polymerization associated with G2/M arrest and apoptotic cell death. More recently, Pontes et al. showed that newly synthesized chromene derivatives (compounds 5c, 5e, and 5i) reduced cell viability in luminal A, MCF-7, TNBC, and Hs578T breast cancer cell lines. However, Hs578T showed a much weaker response to these compounds than MCF-7 cells. Compound 5c, the most effective compound, induced G2/M arrest and apoptotic cell death in MCF-7 cells. Morphological observation of MCF-7 treated with compound 5c revealed disruption in the organization of the microtubule network [40]. Thus, the inhibition of the cell cycle at G2/M and activation of apoptosis is a common mechanism for microtubule-destabilizing chromenes. Our results are consistent with these findings. Here, we found that chromenes C1 and C2 induced cell mitotic arrest and cell death in TNBC. However, our compounds are the first chromenes that also show the induction of cell multinucleation, disruption of the F-actin cytoskeleton, and senescence. In addition, C1 and C2 are the first chromene compounds to exhibit selective activity against TNBC. Microtubules and actin cooperate together to modify cell morphology and establish cell polarity. They do so either directly or by regulating signaling molecules [41]. Several signaling proteins, motor proteins, and other proteins associate, directly or indirectly, with microtubules and actin, and contribute to bridging the components of the cytoskeleton [42]. Thus, given the interconnection between various cytoskeletal polymers, changes in one polymer may affect other polymers. Studies have suggested that inhibition of microtubule polymerization by microtubule-destabilizing drugs, or their stabilization by microtubule-stabilizing compounds, can alter actin abundance. This can lead to changes in F-actin organization and loss of cell polarization, thus impacting the cytoskeletal network [43]. For example, Pletjushkina et al. reported that taxol induced a profound alteration in the distribution of actin filaments in rat fibroblasts [44]. A similar effect was also observed in paclitaxel- or docetaxel-treated MCF-7 cells [45]. Another study by Bijman et al. showed that docetaxel and vinblastine induced incorrect cell polarization and a reduction in stress fibers in HUVEC cells [46]. Our results were similar to these findings, in that we also observed the inhibition of microtubule polymerization by chromene administration, as well as a marked loss of actin stress fibers in MDA-MB-231 cells (Figure 10). Instead of stress fiber formation, we observed a marked increase of cortical actin fibers. To the best of our knowledge, our study is the first to show that chromenes, in addition to their microtubule destabilizing–activity, can also affect F-actin organization. It is notable that the mechanism by which microtubule disruption causes disruption of the organization of the actin cytoskeleton remains poorly explored. Even though many chromene variants have been reported to inhibit tubulin polymerization, little is known regarding their mechanisms of action. Some studies have reported that chromene derivatives such as 4-aryl-4H-chromene (compound 1c) [47] and 4H-chromene (compound 4b and 4e) [48] can inhibit tubulin polymerization by binding to the colchicine binding site. However, these studies relied only on in vitro microtubule polymerization assays and in silico docking data. No cellular or biochemical evidence supporting these conclusions has yet been provided. Here, we showed that our novel compounds C1 and C2 efficiently inhibited microtubule polymerization by immunofluorescence and Western blotting detection of microtubule filaments. In addition, our molecular docking data showed that C1 and C2 could dock best in the colchicine binding site, in a position similar to that of colchicine [49]. This docking was largely aided by hydrophobic interactions, which is characteristic of molecules that bind in this cavity [50]. The residues that interacted with colchicine were also observed to form hydrophobic contacts with both C1 and C2. The binding of molecules in this site, in a colchicine-like pose, is expected to affect the ability of the α- and β-tubulin heterodimer to form a straight conformation. When microtubule dynamics are affected, mitotic spindles cannot form properly. This will cause prolonged mitotic arrest, which in turn leads to growth arrest and cell death [51]. In some cases, cells can exit prolonged mitotic arrest, a phenomenon known as mitotic slippage, which leads to the formation of multiple nuclear compartments, commonly called multinucleation, as a result of improper chromosome segregation and cytokinesis [51,52]. Multinucleated cells can then enter either senescence, or simply die by apoptosis following slippage [52]. To date, the molecular mechanisms that determine the choice between cell death and senescence remain unclear. In some cancer cell lines, post-slippage apoptosis is the major type of cell death induced in response to anti-mitotic drug treatment [53]. In addition, DNA damage seems to play a major role in triggering post-slippage apoptosis [54]. Hart et al. showed that multinucleated cells exhibited the highest incidence of DNA damage, as revealed by the large number of γH2AX foci in over 90% of multinucleated cells [55]. Paclitaxel, an anti-mitotic drug that targets microtubule stabilization, was shown to induce post-slippage multinucleation associated with accumulation of DNA damage and massive apoptosis in Human Bone Osteosarcoma U-2 OS cells [54]. Moreover, the degree of post-slippage multinucleation is correlated with DNA damage and apoptosis [54]. Our results suggest that chromenes C1 and C2 target TNBC through a mechanism similar to that of paclitaxel. We also demonstrated that chromenes C1 and C2 induced mitotic arrest, multinucleation, and DNA damage, ultimately promoting apoptotic cell death. Senescence has been reported to limit tumorigenesis and to foster anti-proliferative responses to cancer therapies [52]. In some cases, senescence is regarded as a tumor suppressing process, and prosenescence approaches have been proposed as promising cancer therapeutic frameworks [56]. Senescent cells, which are permanently growth-arrested but metabolically active, exhibit a complex senescent cell secretome, termed the senescence-associated secretory phenotype (SASP). SASP regulates the recruitment of immune cells to promote the immune clearance of senescent cells [57]. Growth arrest in senescent cells is achieved and maintained in part through the upregulation of the specific CKI p16, p21, and p27 [22,34,35,36]. p21 appears to be more involved in cell cycle blocks associated with early senescence, whereas p16 is more likely important for the maintenance of the senescence-associated phenotype [58]. Cells respond to DNA damage by inducing the expression of genes responsible for the senescence-associated phenotype [28]. The cellular choice between apoptosis or senescence is dependent, at least in part, on the level of DNA damage; minor DNA damage can induce senescence without causing cell death. Salinomycin, a monocarboxylic polyether antibiotic isolated from Streptomyces albus has been shown to induce both senescence and apoptosis in MDA-MB-231 cells, depending on the amount of DNA damage induced [28]. In that study, limited DNA damage triggered rapid senescence and extensive DNA damage triggered apoptosis [28]. Here, we showed that DNA damage occurred in multinucleated cells in response to chromene treatment. We hypothesized that the amount of DNA damage within each cell was the determining factor that determined whether multinucleated cells would undergo senescence or apoptosis. Microtubules and actin filament function cooperatively to orchestrate cell motility, a process crucial for tumor invasion [59]. Actin stress fibers are important actors in cancer cell invasion—a hallmark of metastasis that remains the prime cause of cancer-related mortality—by mediating cellular polarity and motility [60]. Microtubule-targeting drugs (either microtubule stabilizing or destabilizing) have been reported to exert a potent inhibitory effect, at noncytotoxic concentrations, on the migration of various types of invasive cancer cells including TNBC cells [61]. However, very few studies have investigated the effect of microtubule-targeting drugs on the integrity of the actin cytoskeleton in cancer cells. For example, AB 186, a troglitazone derivative and microtubule-stabilizing compound, inhibits the migration of the two highly metastatic TNBC cell lines, MDA-MB-231 and Hs578T [62]. In addition, AB 186 has been shown to promote microtubule stabilization via direct binding to β-tubulin. AB 186 was also shown to affect an unorganized actin network in MDA-MB-231 cells [62]. Troglitazone itself was also shown to inhibit the migration of highly metastatic PK-1 (pancreatic) and ES-2 (ovarian) cancer cells via inhibition of actin polymerization, lamellipodia formation, and inducing a decrease in the number of actin stress fibers [63,64]. Remarkably, the inhibition of cell migration can also occur in cancer cells with defective actin organization independently of microtubule integrity. For example, Nimbolide, a major bioactive compound present in neem leaves, is an inhibitor that has been shown to induce the depolymerization of actin filaments. In one study, nimbolide dramatically and significantly inhibited the migration of the TNBC and MDA-MB-231 cell lines independently of microtubule network [65]. Here, we showed that chromenes C1 and C2 both significantly inhibited the formation of actin stress fibers and consequently impaired the migratory ability of MDA-MB-231 cells. Hence, our study provides support for the notion that the disruption of actin filaments, a consequence of microtubule polymerization or depolymerization, is sufficient to inhibit the migration of cancer cells. Therefore, this finding opens doors for further tests of the integrity of the F-actin network and its consequences in cancer cells treated with microtubule-targeting drugs. Moreover, the disruption or reorganization of the actin network may represent a common mechanism of action. Microtubules play an essential role in orchestrating endothelial cell motility and angiogenesis. Angiogenesis, the process of new blood vessel formation, represents a keystone for both tumor progression and metastasis. Thus, targeting tumor vasculature can inhibit both tumor growth and metastasis [66], and is therefore regarded as a promising anticancer strategy. Microtubule-targeting drugs have gained much attention recently as potential tumor-selective antiangiogenic and vascular-disrupting agents as they possess the ability to suppress microtubule dynamics [67]. Furthermore, several microtubule-targeting drugs, including vinblastine [46] and colchicine [67], both of which destabilize microtubules, were shown to inhibit HUVEC motility, and thus angiogenesis, at concentrations that promote microtubule depolymerization but do not affect cell proliferation [46,67]. Similarly, subtoxic concentrations of paclitaxel [67], docetaxel [46], and epothilone [46], three microtubule-stabilizing drugs, have been reported to inhibit endothelial cell motility via interfering in microtubule dynamics [46,67]. Accordingly, suppressing microtubule dynamics, through microtubule destabilization or stabilization, may be sufficient to prevent angiogenesis. Here, we found that chromenes C1 and C2 both significantly prevented the formation of capillary-like structures in an in vitro tubule formation assay at concentrations that showed no cytotoxicity to HUVECs, even following long exposure times (e.g., 24 h). Consistent with previous findings, we postulate that chromenes C1 and C2 may inhibit angiogenesis, at least partly, via the destabilization of the microtubule network.

Our findings are summarized in Figure 12, which depicts the effect of two novel chromene derivatives C1 and C2, which we synthesized and characterized, against two TNBC cell lines. Treatment with C1 and C2 caused microtubule depolymerization that ultimately led to mitotic arrest in TNBC. These mitotically arrested cells then exited mitosis and gave rise to multinucleated cells, which in turn underwent either apoptosis, probably in response to extensive DNA damage, or remained permanently growth-arrested (senescent) via sustained expression of p21. Thus, C1 and C2, via disruption of the F-actin cytoskeleton, block the migration and thus invasiveness of TNBC cells. In addition, C1 and C2 act as potent antiangiogenic compounds, likely via inhibition of migration of HUVEC cells, due to microtubule depolymerization. Taken together, our results provide evidence for the potential of these compounds in breast cancer management, although further pre-clinical and clinical studies are still warranted.